Brief Summary
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Protocol Interventions
Drug: Anastrozole, Drug: Letrozole, Drug: Exemestane, Drug: Tamoxifen